<DOC>
	<DOC>NCT01605396</DOC>
	<brief_summary>The purpose of the study is to evaluate the progression free survival (PFS) of ridaforolimus, dalotuzumab and exemestane (R/D/E) compared to the combination of ridaforolimus and exemestane (R/E) in post-menopausal participants with breast cancer.</brief_summary>
	<brief_title>A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Females with a histologically confirmed diagnosis of breast cancer that is metastatic or locally advanced (locally advanced tumors must not be amenable to surgery or radiation therapy with curative intent) with the following pathological characteristics determined locally: estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 (HER2) negative, and Ki67 (a tumor marker) ≥ 15% determined by the central study laboratory Postmenopausal With advanced breast cancer whose disease was refractory to previous letrozole or anastrozole Has at least one confirmed measurable metastatic lesion Has a performance status ≤ 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale Has a life expectancy of at least 3 months Adequate organ function Is receiving any other concurrent systemic tumor therapy, including hormonal agents and HER2 inhibitors Previously received rapamycin or rapamycin analogs, including ridaforolimus, temsirolimus, or everolimus Received prior treatment with Insulinlike Growth Factor 1 Receptor (IGF1R) inhibitors, Phosphatidylinositol 3Kinase (PI3K) inhibitors, or other experimental agents that target PI3K, Protein Kinase B (AKT), or Mammalian Target of Rapamycin (mTOR) pathway Is receiving chronic corticosteroids administered at doses greater than those used for normal replacement therapy Has active brain metastasis or leptomeningeal carcinomatosis; patients with adequately treated brain metastases are eligible if they meet certain criteria Known allergy to macrolide antibiotics Has an active infection requiring antibiotics Significant or uncontrolled cardiovascular disease Poorly controlled Type 1 or 2 diabetes Is known to be Human Immunodeficiency Virus (HIV) positive Has a known history of active hepatitis B or C. Healthy carriers of hepatitis B are not allowed on this study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>